



# BLOOD DISORDERS

 Mosby's Clinical Nursing Series



Anne E. Belcher

# **BLOOD DISORDERS**

**ANNE E. BELCHER, PhD, RN**

Professor of Oncology Nursing,  
American Cancer Society;  
Associate Professor,  
University of Maryland School of Nursing,  
University of Maryland at Baltimore,  
Baltimore, Maryland



St. Louis Baltimore Boston Chicago London Philadelphia Sydney Toronto



Dedicated to Publishing Excellence

**Publisher: Alison Miller**  
**Editor: Sally Schrefer**  
**Developmental Editor: Penny Rudolph**  
**Project Manager: Mark Spann**  
**Production Editors: Julie Zipfel, Christine O'Neil**  
**Layout: Doris Hallas**

*Acknowledgment*

The author wishes to acknowledge the contributions of the University of Maryland School of Nursing, the University of Maryland Cancer Center, and the Shock Trauma Center STAT Laboratory and Blood Bank of the University of Maryland Hospital.

Copyright © 1993 by Mosby-Year Book, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher.

Permission to photocopy or reproduce solely for internal or personal use is permitted for libraries or other users registered with the Copyright Clearance Center, provided that the base fee of \$4.00 per chapter plus \$.10 per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, MA 01970. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collected works, or for resale.

Printed in the United States of America

Mosby-Year Book, Inc.  
11830 Westline Industrial Drive  
St. Louis, Missouri 63146

**Library of Congress Cataloging-in-Publication Data**

Belcher, Anne E.

Blood disorders / Anne E. Belcher.  
p. cm. — (Mosby's clinical nursing series)  
Includes bibliographical references and index.  
ISBN 0-8016-7801-3

1. Blood—Diseases—Nursing. I. Title II. Series.  
[DNLM: 1. Blood—nurses' instruction. 2. Hematologic Diseases—  
—nursing. WY 152.5 B427b 1993]

RC636.B37 1993

616.1'5—dc20

DNLM/DLC

for Library of Congress

93-7369  
CIP

# Contributors

**CHRISTINE L. MUDGE-GROUT, RN, MS,  
CNN**

Clinical Nurse Specialist,  
Assistant Clinical Professor,  
University of California at San Francisco,  
San Francisco, California  
(*Lymph Node Assessment*)

**KATHERINE STEFOS, PHD, RPH**

The University of Texas  
M.D. Anderson Cancer Center,  
Division of Pharmacy,  
Houston, Texas  
(*Pharmacologic Agents*)

**ROBERTA STROHL, RN, MN**

Clinical Nurse Specialist,  
Department of Radiation Oncology,  
University of Maryland at Baltimore,  
Baltimore, Maryland  
(*Radiation Therapy*)

**CAROL S. VIELE, RN, MS**

Clinical Nurse Specialist, Department of Nursing,  
Oncology/Hematology, Bone Marrow Transplant;  
Assistant Clinical Professor,  
University of California at San Francisco,  
San Francisco, California  
(*Bone Marrow Transplantation*)

*Original illustrations by*

**GEORGE J. WASSILCHENKO**

Tulsa, Oklahoma

*and*

**DONALD P. O'CONNOR**

St. Peters, Missouri

*Original photography by*

**PATRICK WATSON**

Poughkeepsie, New York

# Preface

*Blood Disorders* is the eleventh volume in *Mosby's Clinical Nursing Series*, a new kind of resource for practicing nurses.

The *Series* is the result of the most elaborate market research ever undertaken by Mosby. We first surveyed hundreds of working nurses to determine what kinds of resources practicing nurses want to meet their advanced information needs. We then approached clinical specialists, proven authors and experts, and asked them to develop a format that would meet the needs of nurses in practice. This format was presented to nine focus groups composed of working nurses and refined between each group. In the later stages we published a 32-page, full-color sample so that detailed changes could be made to improve physical layout and appearance, section by section and page by page. The result is a new genre of professional books for nursing professionals.

*Blood Disorders* begins with a clear and concise discussion of the anatomy and physiology of the blood and blood-forming organs. The first chapter includes a variety of illustrations that depict sometimes difficult-to-visualize aspects of normal and abnormal cellular generation and function.

Chapter 2 is a pictorial guide to the nurse's assessment of the body systems affected by blood disorders. Clear, full-color photographs show proper position and technique in sharp detail, augmented by concise instructions, rationales, and tips.

Chapter 3 presents the latest in diagnostic tests, using full-color photographs of equipment, techniques, monitors, and output. A consistent format for each procedure provides information about the purpose of the test, indications and contraindications, and nursing care associated with each test, including patient teaching. Inside the front cover of the book are tables of normal laboratory values.

Chapters 4 through 9 present the nursing care of patients experiencing specific blood disorders and the major surgical and therapeutic interventions. Chapter 4 focuses on erythrocytic disorders; Chapter 5 on leukocytic disorders; Chapter 6 on thrombocytic disorders; Chapter 7 on myelodysplastic syndromes; Chapter 8 on multiple myeloma; and Chapter 9 on lymphomas. Information on pathophysiology answers questions nurses

often have. Definitive diagnostic tests and the physician's treatment plan are briefly reviewed to promote collaborative care among members of the health team.


The heart of the book is the nursing care, presented according to the nursing process. These pages are bordered in blue to make them easy to find and use on the unit. The nursing care is structured to integrate the five steps of the nursing process, centered around appropriate nursing diagnoses accepted by the North American Nursing Diagnosis Association (NANDA). The material can be used to develop individualized care plans quickly and accurately, and it meets the standards of nursing care required by the Joint Commission on the Accreditation of Healthcare Organizations (JCAHO). By facilitating the development of individualized and authoritative care plans, this book can actually save you time to spend on direct patient care.

Chapter 10 describes therapies, including surgery, radiation, chemotherapy, and bone marrow transplantation. Supportive therapies such as blood and blood-component therapy, nutritional support, and pain management are also described.

In response to requests from scores of nurses participating in our research, a distinctive feature of this book is its use in patient teaching. Background information on diseases and medical interventions enables nurses to answer with authority questions patients often ask. The illustrations in the book, particularly those in the color atlas (Chapter 1) and the chapter on diagnostic procedures (Chapter 3), are specifically designed to support patient teaching. Chapter 11 consists of 15 patient teaching guides written to be copied, distributed to patients and their families, and used for self-care after discharge. In addition, patient teaching sections in each care plan provide nurses with checklists of concepts to teach, promoting this increasingly vital aspect of care.

The book concludes with a concise guide to drugs used for the treatment of blood disorders, and, inside the back cover, a resource section directs you to organizations and other resources for nurses and patients.

We hope this book contributes to the advancement of professional nursing by serving as a first step toward a body of professional literature for nurses to call their own.



Inguinal lymph nodes G.J. Wassilchenko

Hematolympathic components


# Contents

## 1 Color atlas of the blood and blood-forming organs, 1



## 2 Assessment, 13

- History and interviewing, 13
  - Psychosocial/developmental assessment, 15
- Physical examination, 15
  - Skin, hair, and nails, 15
  - Lymphatic assessment, 16
  - Cardiovascular function, 22
  - Respiratory function, 23
  - Neuromuscular/musculoskeletal function, 24
  - Sensory function, 25
  - Pain assessment, 26
  - The abdomen, 26
  - Renal function, 28
  - Genital/sexual function, 29



## 3 Diagnostic procedures, 31

- Complete blood count (CBC) and differential, 31
- Hemoglobin electrophoresis, 34
- Erythrocyte sedimentation rate, 35
- Peripheral blood smear, 35
- Reticulocyte count, 35
- Iron level and total iron-binding capacity, 36
- Serum ferritin, 36
- Serum bilirubin, 37
- Sickle cell, 37
- Immuno-hematologic tests (ABO blood typing, Direct Coombs', Indirect Coombs'), 37
  - Glucose-6-phosphate dehydrogenase, 38
- Vitamin B12 assay (Schilling test), 38
- Serum protein electrophoresis, 39





Uric acid, 40  
 Lactic dehydrogenase (LDH), 40  
 Serum calcium, 40  
 Folic acid, 41  
 Blood culture, 41  
 Prothrombin time, 41  
 Partial thromboplastin time (activated), 42  
 Platelet count, 42  
 Bleeding time, 42  
 Coagulating factors concentration, 43  
 Fibrin degradation products, 43  
 Urine test, 44  
 Bone marrow examination, 45  
 Wound culture, 47  
 Liver scan, 47  
 Lymphangiography, 48  
 Lymph node biopsy, 49  
 Histocompatibility testing, 49  
 Cytogenetic studies, 50  
 Monoclonal antibodies, 50

#### 4 **Erythrocytic disorders**, 51

Posthemorrhagic anemia, 53  
 Iron-deficiency anemia, 57  
 Pernicious anemia, 62  
 Aplastic anemia, 67  
 Hemolytic anemia, 70  
 Sickle disease, 74  
 Thalassemias, 83  
 Polycythemias, 87

#### 5 **Leukocytic disorders**, 93

Leukocytosis, 93  
 Lymphocyte deficiency disorders, 98  
 Leukemia, 98

#### 6 **Thrombocytic disorders**, 112

Thrombocytopenia, 114  
 Disseminated intravascular coagulation  
 syndrome, 120  
 Hemophilia, 127





7 **Myelodysplastic syndromes,** 131

8 **Multiple myeloma,** 137

9 **Lymphomas,** 144

- Hodgkin's disease, 144
- Non-Hodgkin's lymphoma, 151
- Cutaneous T-cell lymphoma, 157

10 **Therapeutic interventions,** 160

- Blood transfusions, 160
- Bone marrow transplantation, 161
- Splenectomy, 176
- Radiation therapy, 176
- Chemotherapy, 188
- Nutritional support, 203
- Pain management, 205

11 **Patient teaching guides,** 208

- General safety precautions, 209
- Therapeutic exercise: focus on walking, 211
- Dealing with stress, 213
- Quitting smoking, 215
- Anticoagulant therapy, 216
- Subcutaneous heparin self-injection, 217, 218
- Care of the Hickman-Broviac external venous catheter, 219
- Care of the implanted port, 220
- Dealing with loss of appetite, nausea and vomiting, and stomatitis, 221
- Dealing with the effects of bone marrow suppression, 222
- Skin care during external beam radiation therapy, 223
- Managing pain without drugs, 224
- Bone marrow harvest, 225
- Clinical trials—what are they?, 226
- Genetic counseling, 227

12 **Pharmacologic agents,** 228



# Color Atlas of the Blood and Blood-Forming Organs

## HEMATOLYMPHATIC SYSTEM

The hematolymphatic system is composed of blood and blood-forming organs, the bone marrow, spleen, liver, and lymphatics.

### BLOOD AND ITS COMPONENTS

Blood, which circulates continuously through the heart and vascular system, performs numerous vital functions (see box).

The major characteristics of blood include color (arterial blood is bright red; venous blood is dark red); viscosity (blood is three to four times thicker than water); reaction (the pH is 7.35 to 7.4); and volume (adults have approximately 70 to 75 ml/kg of body weight, or 5 to 6 L).

Blood is a suspension of particulate matter in an aqueous solution of colloid and electrolytes that serves as a medium of exchange between body cells and the exterior. It also has protective properties that benefit the body and the blood itself. The liquid portion of blood, **plasma**, is a suspension of colloid, electrolytes, proteins, and numerous other substances (Table 1-1). The concentration of these substances varies on the

basis of diet, metabolic demand, hormones, and vitamins. **Serum** is plasma that has had fibrinogen (a clotting factor) or some other unwanted or unneeded substance removed from the sample in the laboratory.

Plasma is about 90% water and 10% dissolved substances (solutes). The dominant substances in weight are the plasma proteins, which are classified as albumins; globulins (immunoglobulins and gamma-globulins); and clotting factors, primarily fibrinogen.

The plasma proteins are synthesized in the liver, except for the **immunoglobulins**, which are synthesized by lymphocytes in the lymph nodes and other lym-

### FUNCTIONS OF BLOOD

- Transport of oxygen and absorbed nutrients to cells
- Transport of waste products to kidneys, skin, and lungs
- Transport of hormones from endocrine glands to other tissues
- Protection of the body from life-threatening microorganisms
- Regulation of body temperature by heat transfer

Table 1-1

## ORGANIC AND INORGANIC COMPONENTS OF ARTERIAL PLASMA

| Constituent  | Amount/concentration   | Major functions  |
|--|--|--|
| <b>Water</b>                                       | 93% of plasma weight   | Medium for carrying all other constituents   |
| <b>Electrolytes</b>                                | Total <1% of plasma weight   | Maintain water in extracellular compartment; act as buffers; function in membrane excitability   |
| Sodium (Na <sup>+</sup> )                          | 142 mEq/L (142 mM)   |  |
| Potassium (K <sup>+</sup> )                        | 4 mEq/L (4 mM)   |  |
| Calcium (Ca <sup>++</sup> )                        | 5 mEq/L (2.5 mM)   |  |
| Magnesium (Mg <sup>++</sup> )                      | 3 mEq/L (1.5 mM)   |  |
| Chloride (Cl <sup>-</sup> )                        | 103 mEq/L (103 mM)   |  |
| Bicarbonate (HCO <sub>3</sub> <sup>-</sup> )       | 27 mEq/L (27 mM)   |  |
| Phosphate (mostly HPO <sub>4</sub> <sup>2-</sup> ) | 2 mEq/L (1 mM)   |  |
| Sulfate (SO <sub>4</sub> <sup>2-</sup> )           | 1 mEq/L (0.5 mM)   |  |
| <b>Proteins</b>                                    | 7.3 g/dl (2.5 mM)  | Provide colloid osmotic pressure of plasma; act as buffers; bind other plasma constituents (e.g., lipids, hormones, vitamins, metals); clotting factors; enzymes; enzyme precursors; antibodies (immune globulins); hormones |
| Albumins   | 4.5 g/dl   |  |
| Globulins  | 2.5 g/dl   |  |
| Fibrinogen   | 0.3 g/dl   |  |
| <b>Gases</b>                                       |  |  |
| Carbon dioxide (CO <sub>2</sub> ) content          | 22-20 mmol/L plasma  | By-product of oxygenation, most carbon dioxide content is from bicarbonate and acts as a buffer  |
| Oxygen (O <sub>2</sub> )                           | Pao <sub>2</sub> 80 torr or greater (arterial); Pvo <sub>2</sub> 30-40 torr (venous) | Oxygenation  |
| Nitrogen (N <sub>2</sub> )                         | 0.9 ml/dl  | By-product of protein catabolism   |
| <b>Nutrients</b>                                   |  | Provide nutrition and substances for tissue repair   |
| Glucose and other carbohydrates                    | 100 mg/dl (5.6 mM)   |  |
| Total amino acids                                  | 40 mg/dl (2 mM)  |  |
| Total lipids                                       | 500 mg/dl (7.5 mM)   |  |
| Cholesterol  | 150-250 mg/dl (4-7 mM)   |  |
| Individual vitamins                                | 0.0001-2.5 mg/dl   |  |
| Individual trace elements                          | 0.001-0.3 mg/dl  |  |
| <b>Waste products</b>                              |  |  |
| Urea (BUN)   | 7-18 mg/dl (5.7 mM)  | End product of protein catabolism  |
| Creatinine (from creatinine)                       | 1 mg/dl (0.09 mM)  | End product from energy metabolism   |
| Uric acid (from nucleic acids)                     | 5 mg/dl (0.3 mM)   | End product of protein metabolism  |
| Bilirubin (from heme)                              | 0.2-1.2 mg/dl (0.003-0.018 mM)   | End product of red blood cell destruction  |
| <b>Individual hormones</b>                         | 0.000001-0.05 mg/dl  | Functions specific to target tissue  |

(From Vander, Sherman, and Luciano.)<sup>61a</sup>

phoid tissues. **Albumin** is essential for regulating the passage of water and solutes through the capillaries. Because these molecules are large and do not diffuse freely through the vascular endothelium, they provide the critical colloid osmotic pressure that regulates the passage of water and solutes through the microcirculation. Albumin also serves as a carrier molecule for normal blood components and exogenous agents such as drugs. The immunoglobulins (antibodies) are synthesized by plasma cells in the lymphoid organs. The antibodies are IgA, IgG, IgM, IgD, and IgE, and they are critical for defense against infectious microorganisms.

The **clotting factors** (Table 1-2) stop bleeding from damaged blood vessels. **Fibrinogen**, the most plentiful of the clotting factors, is the precursor of the fibrin clot. **Hemostasis**, which means arrest of bleeding, involves a complex sequence of events, including vasoconstriction, formation of a platelet plug, activation of the coagulation cascade, and formation of a blood clot (Figures 1-1 and 1-2 and box on p. 3).

Other plasma proteins include complement proteins involved in the immune response, a variety of enzymes and their inhibitors, and specific carriers of such elements as iron and copper.




FIGURE 1-1 Coagulation cascade. (From McCance and Huether).<sup>40</sup>

Table 1-2

**CLOTTING FACTORS**

| <b>International nomenclature</b> | <b>Synonym</b>  | <b>Substance</b>                | <b>Source</b>                                    | <b>Enzymatic function</b>  | <b>Pathway of activation</b>    |
|-----------------------------------|---|---------------------------------|--|--|---------------------------------|
| I                                 | Fibrinogen  | Plasma protein                  | Liver  | Precursor of fibrin  | Final common pathway            |
| II                                | Prothrombin   | Plasma protein                  | Liver  | Precursor of thrombin  | Final common pathway            |
| III                               | Tissue thromboplastin<br>Tissue factor<br>Thrombokinas  | Lipoprotein and phospholipid    | Released from damaged tissues                    | Activates prothrombin  | Extrinsic pathway               |
| IV                                | Calcium ion   | Ion in plasma                   | Diet and bones                                   | Activates prothrombin and fibrin formation   | All                             |
| V                                 | Labile factor<br>Proaccelerin accelerator globulin (AcG)<br>Thrombogen  | Plasma protein                  | Liver  | Accelerates conversion of prothrombin to thrombin  | Final common pathway            |
| VI                                | Obsolete; same as V   |                                 |  |  |                                 |
| VII                               | Serum prothrombin conversion factor<br>Proconvertin<br>Stable factor  | Plasma protein                  | Liver  | Accelerates conversion of prothrombin to thrombin; part of enzyme complex                              | Extrinsic pathway               |
| VIII                              | Antihemophilic globulin (AGH)<br>Antihemophilic factor (AHF)<br>Thromboplastinogen<br>Platelet cofactor 1                                     | Plasma protein (three subunits) | Large molecular weight<br>Subunit by endothelium | Associated with platelet factor 3 and Christmas factor (IX), activates prothrombin (II)                | Intrinsic pathway               |
| IX                                | Plasma thromboplastin component (PTC)<br>Christmas factor<br>Antihemophilic factor B<br>Autoprothrombin II (protein C)<br>Platelet cofactor 2 | Plasma protein                  | Liver  | Associated with platelet factors 3 and 6; activates prothrombin  | Intrinsic pathway               |
| X                                 | Stuart-Prower factor<br>Stuart factor<br>Autoprothrombin III  | Plasma protein                  | Liver and plasma                                 | Activated by Hageman factor  | Extrinsic and intrinsic pathway |
| XI                                | Plasma thromboplastin antecedent (PTA)<br>Antihemophilic factor C   | Plasma protein                  | Possibly liver                                   | Activated by Hageman factor; accelerates thrombin formation; substrate for activator enzymatic complex | Intrinsic pathway               |
| XII                               | Hageman factor<br>Contact factor<br>Glass factor<br>Antihemophilic factor D   | Plasma protein                  | Liver and (plasma?)                              | Involved in first step of activation of intrinsic pathway; activates XI                                | Intrinsic pathway               |

Table 1-2

CLOTTING FACTORS—cont'd

| International nomenclature      | Synonym  | Substance      | Source                                   | Enzymatic function                                       | Pathway of activation   |
|---------------------------------|--|----------------|--|--|-------------------------|
| XIII                            | Fibrin-stabilizing factor (FSF)<br>Fibrinase<br>Fibrinoligase<br>Laki-Lorand factor (LLF)<br>Plasma transglutaminase | Plasma protein | Present in plasma and platelets<br>Liver | Produces stronger fibrin clot; stabilizes clot formation | Common                  |
| High-molecular-weight kininogen | HMWK<br>Fitzgerald factor<br>Williams factor<br>Fluajecac factor<br>Reid factor<br>Washington factor                 | Alpha-globulin | Tissues                                  | Activates contraction of clot                            | Intrinsic kinin cascade |
| Prekallikrein                   | Fletcher factor  | Gamma-globulin | Tissues                                  | Activates contraction of clot                            | Intrinsic kinin cascade |

The factors are numbered in the order of their discovery. Numerals do not denote their sequence of activation in the coagulation cascade. (From McCance and Huether).<sup>40</sup>




FIGURE 1-2 Platelet degranulation. PAF, Platelet-activating factor. (From McCance and Huether).<sup>40</sup>



Table 1-3

## CELLULAR COMPONENTS OF THE BLOOD

| Cell                         | Structural characteristics                           | Normal amounts in circulating blood                 | Function  | Life span                        |
|------------------------------|--|---|---|----------------------------------|
| Erythrocyte (red blood cell) | Nonnucleated cytoplasmic disk containing hemoglobin  | 4.2-6.2 million/mm <sup>3</sup>                     | Gas transport to and from tissue cells and lungs  | 80-120 days                      |
| Leukocyte (white blood cell) | Nucleated cell                                       | 5,000-10,000/mm <sup>3</sup>                        | Bodily defense mechanisms   | See below                        |
| Lymphocyte                   | Mononuclear immunocyte                               | 25%-33% of leukocyte count (leukocyte differential) | Humoral and cell-mediated immunity  | Days or years, depending on type |
| Monocyte and macrophage      | Large mononuclear phagocyte                          | 3%-7% of leukocyte differential                     | Phagocytosis; mononuclear phagocyte system  | Months or years                  |
| Eosinophil                   | Segmented polymorphonuclear granulocyte              | 1%-4% of leukocyte differential                     | Phagocytosis; antibody-mediated defense against parasites, allergic reactions; associated with Hodgkin disease, recovery phase of infection | Unknown                          |
| Neutrophil                   | Segmented polymorphonuclear granulocyte              | 57%-67% of leukocyte differential                   | Phagocytosis, particularly during early phase of inflammation   | 4 days                           |
| Basophil                     | Segmented polymorphonuclear granulocyte              | 0-0.75% of leukocyte differential                   | Unknown, but associated with allergic reactions and mechanical irritation   | Unknown                          |
| Thrombocyte (platelet)       | Irregularly shaped cytoplasmic fragment (not a cell) | 140,000-340,000/mm <sup>3</sup>                     | Hemostasis following vascular injury; normal coagulation and clot formation/retraction  | 8 to 11 days                     |

(From McCance and Huether.)<sup>40</sup>

**Lipoproteins** are carried through the blood as complexes with **plasma proteins**. The lipoproteins include the plasma lipids, triglycerides, phospholipids, cholesterol, and fatty acids.

The **electrolytes** (sodium, potassium, calcium, magnesium, chloride, bicarbonate, phosphate, and sulfate) maintain the osmolarity and pH of the blood within a physiologic range.

The cellular elements of the blood include red blood cells (erythrocytes), white blood cells of several types (leukocytes), and platelets (thrombocytes) (Table 1-3). All of these cells are believed to be derived from a single stem cell, which divides and matures to produce three distinct types of cells with different functions, properties, and characteristics (Figure 1-3). Blood cell production (**hematopoiesis**) occurs in the bone marrow; it is a two-stage process involving mitotic division (**proliferation**) and maturation (**differentiation**). Each type of blood cell has parent cells (**stem**

**cells**), which undergo mitosis when they receive specific biochemical signals that populations of circulating blood cells have decreased to a certain point. Proliferation continues until the required number of mature daughter cells has entered the circulation. Hematopoiesis continues throughout life. Blood cell production in tissues other than bone marrow usually is a sign of disease.

### Erythrocytes

Erythrocytes have several principal functions:

- Transport of oxygen to the tissues
- Transport of carbon dioxide to the lungs
- Maintenance of normal blood pH through a series of intracellular buffers

There are approximately 5 million erythrocytes per cubic millimeter of blood; normal hemoglobin is 15 g/dl of blood. Erythrocytes are produced in the red




FIGURE 1-3 Components of blood derived from a single stem cell.






FIGURE 1-4

Iron cycle. Iron (Fe) released from gastrointestinal epithelial cells circulates in the bloodstream associated with its plasma carrier, transferrin. It is delivered to erythroblasts in the bone marrow, where most of it is incorporated into hemoglobin. Mature erythrocytes circulate for approximately 120 days, after which they become senescent and are removed by the mononuclear phagocyte system (MPS). Macrophages of the MPS (mostly in the spleen) break down ingested erythrocytes and return iron to the bloodstream directly or after storing it as ferritin or hemosiderin. (From McCance and Huether.)<sup>40</sup>

bone marrow and found in the ribs, sternum, skull, vertebrae, and bones of the hands, feet, and pelvis. Numerous nutrients are needed for normal cell formation, including iron, vitamin B<sub>12</sub>, folic acid, and pyridoxine. The young reticulocytes released from the bone marrow circulate for 4 days while maturing into adult erythrocytes. The average life span of an erythrocyte is 115 to 130 days; dead cells are eliminated by phagocytosis in the mononuclear phagocyte system, particularly in the spleen and liver.

The size and shape of the erythrocyte are ideal for its function as a gas carrier. It is a small disk with the unique characteristics of biconcavity and reversible deformability. The flattened, biconcave shape provides a surface area to volume ratio that is optimal for the diffusion of gases into and out of the cell. Reversible deformity enables the cell to alter its shape to squeeze

through the microcirculation and then return to normal.

**Hemoglobin**, the iron-containing substance of the red blood cell, is composed of a simple protein called globin and a red compound called heme, which contains iron and porphyrin. Each erythrocyte contains 200 million to 300 million molecules of hemoglobin, which combine chemically with oxygen to form oxyhemoglobin. Hemoglobin also combines with carbon dioxide. These two capacities enable the blood to carry oxygen to the tissues and carbon dioxide to the alveoli and thus to the atmosphere.

Total iron in the body ranges from 2 to 6 g, two thirds of which is contained in hemoglobin (Figure 1-4 illustrates the iron cycle). The rest is stored in the bone marrow, spleen, and liver. Iron is obtained from such rich dietary sources as liver; oysters; lean meat;